In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 51 days of free consultation


Impact of transcatheter mitral valve repair on ventricular arrhythmias

Session Poster session 2

Speaker Charlotte Eitel

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P1106

Authors : C Eitel (Luebeck,DE), J Ledwoch (Luebeck,DE), J Ledwoch (Luebeck,DE), T Stiermeier (Luebeck,DE), S Desch (Luebeck,DE), M Saad (Luebeck,DE), J Vogler (Luebeck,DE), CH Heeger (Luebeck,DE), H Thiele (Luebeck,DE), I Eitel (Luebeck,DE), RR Tilz (Luebeck,DE)


C Eitel1 , J Ledwoch1 , J Ledwoch1 , T Stiermeier1 , S Desch1 , M Saad1 , J Vogler1 , CH Heeger1 , H Thiele1 , I Eitel1 , RR Tilz1 , 1Medical University - Lübeck - Germany ,


Aims: Patients with heart failure and severe mitral regurgitation (MR) have a poor prognosis and carry an increased risk for ventricular arrhythmias. The present study evaluates the impact of transcatheter mitral valve repair using the MitraClip on the potential reduction of ventricular arrhythmias.

Methods: Patients undergoing MitraClip implantation were prospectively enrolled into the present study and received 24h Holter EKG assessment prior to and 6 months after the procedure. In addition left ventricular dimensions and function were assessed at baseline and follow-up.

Results: A total of 50 patients with mainly functional MR (82%) were included. Sustained or nonsustained ventricular tachycardia (sVT/nsVT) occurred in 33% of patients and was reduced to 12% after the procedure (p=0.01). Also, premature ventricular complex burden (PVC) burden = 5% was decreased from 16% to 4% (p=0.04). Patients with persistent (n=3) or new sVT/nsVT (n=3) at follow-up showed a significant decrease in left ventricular ejection fraction (from 43% [38 – 51%] to 38% [30 – 44%]; p=0.01).

Conclusions: Transcatheter mitral valve repair using MitraClip reduced the risk for ventricular arrhythmias in the majority of patients. Patients with persistent or new ventricular arrhythmias after MitraClip implantation showed progression of heart failure and remain at increased risk for pump failure and ventricular arrhythmias.

This content is currently on FREE ACCESS, enjoy another 51 days of free consultation


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are